Abstract: SA-PO396
Dynamics of Amyloid-β and Total Tau in Cerebrospinal Fluid and Plasma of Patients on Hemodialysis
Session Information
- Hemodialysis and Frequent Dialysis - 2
October 26, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 801 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Gorji, Hassan, Renal Research Institute, New York, New York, United States
- Wang, Lin-Chun, Renal Research Institute, New York, New York, United States
- Thwin, Ohnmar, Renal Research Institute, New York, New York, United States
- Chao, Joshua Emmanuel, Renal Research Institute, New York, New York, United States
- Debure, Ludovic, NYU Langone Health, Department of Neurology Center for Cognitive Neurology Alzheimer's Disease Research Center - Biomarker Core, New York, New York, United States
- Grobe, Nadja, Renal Research Institute, New York, New York, United States
- Wang, Xin, Renal Research Institute, New York, New York, United States
- Zhang, Hanjie, Renal Research Institute, New York, New York, United States
- Thijssen, Stephan, Renal Research Institute, New York, New York, United States
- Wisniewski, Thomas, NYU Langone Health, Department of Neurology Center for Cognitive Neurology Alzheimer's Disease Research Center - Biomarker Core, New York, New York, United States
- Kotanko, Peter, Renal Research Institute, New York, New York, United States
Background
While hemodialysis (HD) can reduce Amyloid beta protein (Aβ) in the blood, its impact on cerebrospinal fluid (CSF) Aβ levels has not been studied. This research is the first to investigate the dynamics of Aβ and total tau levels in both CSF and plasma of HD patients.
Methods
Three chronic HD patients with ventriculo-peritoneal shunts participated in this study. The patients underwent thrice weekly high-flux HD. During HD, plasma samples were collected at six different timepoints, shown in figures A1, B1, C1. Two patients had repeated VPS taps to collect CSF samples. One subject was withdrawn over safety concern. Aβ1-40, Aβ1-42, total tau in the CSF and plasma samples were quantified using the Neuro 3-Plex assays (Quanterix, MA, USA).
Results
Our findings indicate a decrease in plasma levels of Aβ1-40 and Aβ1-42 by 40% and 35% respectively, while total tau levels increased by 16% (Figures A1, B1, C1). The mean levels of these proteins in plasma and CSF during the intervals between HD sessions (interdialytic period) are shown in Figures A2, B2, C2. Notably, during the interdialytic intervals, there was an inverse relationship in protein levels: while plasma levels of Aβ1-40, Aβ1-42, and total tau increased, their respective CSF levels decreased (Table1, Figures A2, B2, C2).
Conclusion
This study is the first to demonstrate CSF dynamics of Aβ1-40, and 42, and total tau in HD patients. We observed that after HD, in the interdialytic period, the CSF levels of Aβ1-40 and 42, and total tau declined. Interestingly, while CSF levels of Aβs and total tau decreased during the interdialytic periods, their respective plasma levels tended to increase. The biological significance of these findings warrants further studies.